Literature DB >> 15982573

Synthesis and in vivo evaluation of [11C]PJ34, a potential radiotracer for imaging the role of PARP-1 in necrosis.

Zhude Tu1, Wenhua Chu, Jun Zhang, Carmen S Dence, Michael J Welch, Robert H Mach.   

Abstract

Poly(ADP-ribose) polymerase-1 (PARP-1) is an abundant nuclear enzyme of eukaryotic cells that has been implicated in response to DNA injury. PARP-1 detects single-strand DNA breaks induced by a variety of genotoxic insults. A hyperactivation of PARP-1 is believed to play a critical role in tissues undergoing cellular death by necrosis. Therefore, a radiotracer that could image PARP-1 levels with PET could provide a useful tool in measuring necrosis in a variety of pathological conditions. The phenanthridinone derivative, 2-(dimethylamino)-N-(5,6-dihydro-6-oxophenanthridin-2-yl)acetamide (PJ34), has a high affinity for PARP-1 (IC(50) = 20 nM) and is a suitable lead compound for PET radiotracer development. The synthesis of [(11)C]PJ34 was accomplished by base-catalyzed reaction of the corresponding des-methyl precursor, N-(5,6-dihydro-6-oxophenanthridin-2-yl)-2-(methylamino)acetamide with [(11)C]methyl iodide in DMF. The radiolabeling yield was 60% and the specific activity was approximately 2000 mCi/micromol (decay corrected to E.O.B.). The total radiosynthesis time was approximately 50 min. Preliminary in vivo biodistribution studies in a rodent model of diabetes indicate that [(11)C]PJ34 displays a high uptake in tissues where PARP-1 is hyperactivated. These data indicate that [(11)C]PJ34 may be a useful radiotracer for imaging tissues undergoing cellular death via necrosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15982573     DOI: 10.1016/j.nucmedbio.2005.03.001

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  12 in total

1.  Radiosynthesis and in vivo evaluation of [11C]MP-10 as a PET probe for imaging PDE10A in rodent and non-human primate brain.

Authors:  Zhude Tu; Jinda Fan; Shihong Li; Lynne A Jones; Jinquan Cui; Prashanth K Padakanti; Jinbin Xu; Dexing Zeng; Kooresh I Shoghi; Joel S Perlmutter; Robert H Mach
Journal:  Bioorg Med Chem       Date:  2011-01-22       Impact factor: 3.641

2.  Synthesis, [¹⁸F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography.

Authors:  Dong Zhou; Wenhua Chu; Jinbin Xu; Lynne A Jones; Xin Peng; Shihong Li; Delphine L Chen; Robert H Mach
Journal:  Bioorg Med Chem       Date:  2014-01-24       Impact factor: 3.641

Review 3.  Molecular Imaging of PARP.

Authors:  Brandon Carney; Susanne Kossatz; Thomas Reiner
Journal:  J Nucl Med       Date:  2017-05-04       Impact factor: 10.057

4.  PARP-1 Expression Quantified by [18F]FluorThanatrace: A Biomarker of Response to PARP Inhibition Adjuvant to Radiation Therapy.

Authors:  Samuel Sander Effron; Mehran Makvandi; Lilie Lin; Kuiying Xu; Shihong Li; Hsiaoju Lee; Catherine Hou; Daniel A Pryma; Cameron Koch; Robert H Mach
Journal:  Cancer Biother Radiopharm       Date:  2017-01-24       Impact factor: 3.099

5.  A one-pot radiosynthesis of [18 F]PARPi.

Authors:  Thomas C Wilson; Nagavarakishore Pillarsetty; Thomas Reiner
Journal:  J Labelled Comp Radiopharm       Date:  2020-06-16       Impact factor: 1.921

Review 6.  Opportunities for PET to deliver clinical benefit in cancer: breast cancer as a paradigm.

Authors:  Ian N Fleming; Fiona J Gilbert; Ken A Miles; David Cameron
Journal:  Cancer Imaging       Date:  2010-07-06       Impact factor: 3.909

Review 7.  Imaging the DNA damage response with PET and SPECT.

Authors:  James C Knight; Sofia Koustoulidou; Bart Cornelissen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-01-05       Impact factor: 9.236

Review 8.  Avenues to molecular imaging of dying cells: Focus on cancer.

Authors:  Anna A Rybczynska; Hendrikus H Boersma; Steven de Jong; Jourik A Gietema; Walter Noordzij; Rudi A J O Dierckx; Philip H Elsinga; Aren van Waarde
Journal:  Med Res Rev       Date:  2018-03-12       Impact factor: 12.944

9.  A Radiotracer Strategy to Quantify PARP-1 Expression In Vivo Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor Therapy.

Authors:  Mehran Makvandi; Kuiying Xu; Brian P Lieberman; Redmond-Craig Anderson; Samuel Sander Effron; Harrison D Winters; Chenbo Zeng; Elizabeth S McDonald; Daniel A Pryma; Roger A Greenberg; Robert H Mach
Journal:  Cancer Res       Date:  2016-06-03       Impact factor: 13.312

Review 10.  Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy.

Authors:  Stephen A Jannetti; Brian M Zeglis; Michael R Zalutsky; Thomas Reiner
Journal:  Front Pharmacol       Date:  2020-03-03       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.